Abstract:Background Septal reduction techniques play a pivotal role in mitigating morbidity and mortality among patients with obstructive hypertrophic cardiomyopathy (oHCM). While trans-apical intramyocardial septal radiofrequency ablation (PIMSRA or LIWEN procedure) has shown promise in reducing left ventricular outflow tract (LVOT) gradients and improving symptoms in oHCM patients, it is associated with complications such as cardiac tamponade and atrioventricular block. Objective This study introduces a novel approach for transcatheter radiofrequency ablation of hypertrophic septum via femoral access, utilizing the DragonFire Transcatheter Myocardial Puncture and Radiofrequency Ablation System. We aim to evaluate its safety and medium-term outcomes in patients with oHCM. Methods A prospective, single-center, single-arm study of tf-PIMSRA was conducted in patients with drug-refractory oHCM. Ten patients were enrolled and underwent the procedure under the guidance of transesophageal echocardiography. The primary outcome was 30-day major adverse clinical events, with secondary outcomes including 90-day improvements in outflow obstruction and quality of life. Results All patients, with an average age of 57±10 years, including 4 males, underwent the procedure successfully without any complications, including major adverse clinical events or conduction abnormalities. The average duration of the procedure was 125.2±34.6 minutes, with an average ablation time of 38.69±18.29 minutes and ablation energy of 3.60±1.49KJ. At 90-day follow-up, significant reductions were observed in peak LVOT gradients (resting gradient: from 82.00 [56.00] mmHg to 14.00 [6.25] mmHg; p < 0.001; provoked gradient: from 102.00 [76.25] mmHg to 33.00 [16.50] mmHg; p = 0.002), and interventricular septum thickness (from 22.00 [19.00] mm to 17.00 [15.00] mm; p = 0.002). These improvements were associated with enhancements in NYHA functional classification (from 3.00 [2.75] to 1.00 [1.00]; p < 0.0001), Kansas City Cardiomyopathy Questionnaire scores (from 59.00 [44.50] to 80.00 [77.25]; p < 0.02), 6-minute walk distance (from 441 [400] m to 480 [465] m; p < 0.01), and pro B-type natriuretic peptide levels (from 1738.00 [1113.25] pg/ml to 252.00 [200.00] pg/ml; p = 0.002). All patients achieved New York Heart Association functional class I or II at follow-up. Conclusions Transfemoral PIMSRA appears to be a safe and effective procedure for relieving LVOT obstruction and symptoms in patients with drug-refractory oHCM. These findings support further investigation through randomized clinical trials comparing it with established septal reduction therapies.Patient-Level Outcomes for the trans-fem

Transcatheter Myotomy to Relieve Left Ventricular Outflow Tract Obstruction: The Septal Scoring Along the Midline Endocardium Procedure in Animals

Transcatheter Myotomy to Reduce Left Ventricular Outflow Obstruction

Selective Interventricular Septal Radiofrequency Ablation in Patients with Hypertrophic Obstructive Cardiomyopathy: Who Can Benefit?

A Modified Endocardial Radiofrequency Ablation Approach for Hypertrophic Obstructive Cardiomyopathy Guided by Transthoracic Echocardiography: a Case Series

Percutaneous Transluminal Septal Myocardial Ablation in Hypertrophic Obstructive Cardiomyopathy: Acute Results and Three-Year Noninvasive Follow-Up in 18 Patients.

First-in-Human Transapical Beating-Heart Septal Myectomy in Patients With Hypertrophic Obstructive Cardiomyopathy

Trans-femoral transcatheter intramyocardial septal radiofrequency ablation: a novel therapeutic approach for obstructive hypertrophic cardiomyopathy

Transthoracic Echocardiography Guided Percutaneous Laser Ablation of the Interventricular Septum: A Successful Sheep Model for Septal Thickness Reduction and One Year Follow-Up.

Echocardiography-guided Ethanol Septal Reduction for Hypertrophic Obstructive Cardiomyopathy.

Enlargement of Left Ventricular Outflow Tract Using an Autologous Pericardial Patch for the Anterior Mitral Valve Leaflet and Septal Myectomy Through Trans-mitral Approach for the Treatment of Hypertrophic Obstructive Cardiomyopathy

Transapical beating-heart septal myectomy for recurrent left ventricular outflow tract obstruction after septal reduction therapy in hypertrophic obstructive cardiomyopathy

Transapical ventricular reshaping reduces functional mitral regurgitation and improves ventricular function in a preclinical model of ischemic cardiomyopathy

Longitudinal valvotomy of anterior leaflet for endoscopic transmitral myectomy for hypertrophic obstructive cardiomyopathy

A preoperative planning procedure of septal myectomy for hypertrophic obstructive cardiomyopathy using image-based computational fluid dynamics simulations and shape optimization

Application of special surgical instruments in transaortic septal myectomy for the treatment of hypertrophic obstructive cardiomyopathy

Transcatheter Myotomy for Hypertrophic Obstructive Cardiomyopathy

Percutaneous Intramyocardial Septal Radiofrequency Ablation for Interventricular Septal Reduction: An Ovine Model with 1-Year Outcomes

Clinical Effect of the Modified Morrow Septal Myectomy Procedure for Biventricular Hypertrophic Cardiomyopathy

Transapical intramyocardial septal microwave ablation in treatment of hypertrophic obstructive cardiomyopathy: 12-month outcomes of a swine model

Thoracoscopic Trans-Mitral Myectomy for Hypertrophic Obstructive Cardiomyopathy: a Retrospective Single-Centre Study

Primeval Outcomes of Thoracoscopic Transmitral Myectomy with Anterior Mitral Leaflet Extension for Hypertrophic Obstructive Cardiomyopathy